SEC Info - Thangaraj Immanuel - ‘4’ for 1/2/18 re: Acura Pharmaceuticals, Inc.

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

THANGARAJ IMMANUEL

(Last)

(First)

(Middle)

335 BRYANT STREET

(Street)

PALO ALTO

94301

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
ACURA PHARMACEUTICALS, INC [ ACUR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
1/2/18

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	1/2/18		M ⁽¹⁾		35,714	A	⁽²⁾	59,526 ⁽³⁾	D
Common Stock								1,956,396	I ⁽⁴⁾	By Essex Woodlands Health Ventures Fund V, L.P

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽²⁾ ⁽⁵⁾	1/2/18		M		35,714		⁽⁶⁾	⁽⁶⁾	Common Stock	35,714	⁽⁷⁾	23,809	D
Restricted Stock Units	⁽²⁾ ⁽⁵⁾	1/2/18		D			23,809	⁽⁶⁾	⁽⁶⁾	Common Stock	23,809	$0.4039	0	D
Restricted Stock Units	⁽²⁾ ⁽⁵⁾	1/2/18		A		66,666		⁽⁸⁾	⁽⁸⁾	Common Stock	66,666	⁽⁷⁾	66,666	D

Explanation of Responses:

(1) Represents exchange of restricted stock units.

(2) Par value of $.01 per share must be paid by Reporting Person upon exchange of Restricted Stock Units for stock

(3) Does not include Restricted Stock Units.

(4) The reporting person is a managing director of the general partner of Essex Woodlands Health Ventures Fund V, L.P. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

(5) 1 - for -1

(6) 59,523 Restricted Stock Units were granted on the first business day of January 2017. 25% of such Restricted Stock Units vested on March 31, 2017, 25% vested on June 30, 2017; 25% vested on September 30, 2017 and 25% vested on December 31, 2017. 40% of such Restricted Stock Units are being settled in cash and 60% are being settled in stock, in each case upon payment of par value.

(7) N/A

(8) 25% of Restricted Stock Units vest on the last day of each of March, June, September and December 2018, subject to immediate vesting in the event of a change of control and certain other events. Reporting Person may elect to exchange up to 40% of Restricted Stock Units for cash and the remaining Restricted Stock Units will be exchanged on a one for one basis for common stock, in each case upon payment of, or deduction of par value. Distributions in respect of vested Restricted Stock Units will be made on the first business day of January 2019, or earlier upon a change of control.

Remarks:

	/s/ Immanuel Thangaraj	1/4/18
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

____________ Transaction Codes:
A	Grant, award or other acquisition pursuant to Rule 16b-3(d).
D	Disposition to the Issuer of Issuer equity securities pursuant to Rule 16b-3(e).
M	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.

Thangaraj Immanuel – ‘4’ for 1/2/18 re: Acura Pharmaceuticals, Inc.

On: Thursday, 1/4/18, at 6:27pm ET · For: 1/2/18 · Accession #: 1209191-18-2199 · File #: 1-10113

Previous ‘4’: ‘4’ on 1/4/17 for 1/3/17 · Next: ‘4’ on 1/8/19 for 1/2/19 · Latest: ‘4’ on / for 1/2/24

Statement of Changes in Beneficial Ownership of Securities by an Insider — Form 4 — SEA’34
Filing Table of Contents

This ‘4’ Document is an XML Data File that may be rendered in various formats:

Thangaraj Immanuel – ‘4’ for 1/2/18 re: Acura Pharmaceuticals, Inc.

On: Thursday, 1/4/18, at 6:27pm ET · For: 1/2/18 · Accession #: 1209191-18-2199 · File #: 1-10113

Previous ‘4’: ‘4’ on 1/4/17 for 1/3/17 · Next: ‘4’ on 1/8/19 for 1/2/19 · Latest: ‘4’ on / for 1/2/24

Statement of Changes in Beneficial Ownership of Securities by an Insider — Form 4 — SEA’34Filing Table of Contents

This ‘4’ Document is an XML Data File that may be rendered in various formats:

Statement of Changes in Beneficial Ownership of Securities by an Insider — Form 4 — SEA’34
Filing Table of Contents